Newer drugs like Tirzepatide and Retatrutide, which combine multiple peptides, offer even greater weight loss effects than single GLP1 medications.

An interesting new hypothesis is whether microdosing GLP1 medications in healthy individuals could offer health and lifespan benefits.

GSK invested $720 million in resveratrol research based on initial hype, but the results could not be replicated, leading to a total loss.

The SGLT2 inhibitor canagliflozin, a medication for type 2 diabetes, was found to extend male mice lifespan by 14% in a robust study.

The rigorous Interventions Testing Program found that neither the senolytic fisetin nor the NAD precursor nicotinamide riboside (NR) extended lifespan in mice.

Rapamycin is considered the 'golden child' of longevity research, as it consistently extends both male and female mice lifespan by 17% to 25%.

New small interfering PCSK9 inhibitors can lower LDL cholesterol by about 50% with just one injection every six months, dramatically improving adherence.

Modern non-ablative skin devices offer nearly the same reduction in fine lines and wrinkles as older ablative lasers but without the significant recovery time.